Literature DB >> 11090111

Partial to complete antagonism by putative antagonists at the wild-type alpha(2C)-adrenoceptor based on kinetic analyses of agonist:antagonist interactions.

P J Pauwels1, F C Colpaert.   

Abstract

1. Activation of the recombinant human alpha(2C)-adrenoceptor (alpha(2C) AR) by (-)-adrenaline in CHO-K1 cells transiently co-expressing a chimeric G(alpha q/i1) protein induced a rapid, transient Ca(2+) response with a high-magnitude followed by a low-magnitude phase which continued throughout the recorded time period (15 min). 2. Activation of the alpha(2C) AR by various alpha(2) AR agonists revealed the following rank order of high-magnitude Ca(2+) response [E(max) (%) versus 10 microM (-)-adrenaline]: UK 14304 (102+/-4)=talipexole (101+/-3)=(-)-adrenaline (100)=d-medetomidine (98+/-1)>oxymetazoline (81+/-4) reverse similarclonidine (75+/-5). 3. The methoxy- (RX 821002) and ethoxy-derivatives (RX 811059) of idazoxan and the dexefaroxan analogue atipamezole were fully effective as antagonists of both the high- and the low-magnitude Ca(2+) response. However, though acting as full antagonists of the high-magnitude response, the further putative alpha(2) AR antagonists idazoxan (27%), SKF 86466 (29%) and dexefaroxan (59%) reversed the low-magnitude response only partially. 4. In conclusion, kinetic analyses of agonist : antagonist interactions at the alpha(2C) AR demonstrate a wide spectrum of partial to complete antagonism of the low-magnitude Ca(2+) response for structurally related alpha(2) AR ligands.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090111      PMCID: PMC1572480          DOI: 10.1038/sj.bjp.0703726

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Influence of G protein type on agonist efficacy.

Authors:  Q Yang; S M Lanier
Journal:  Mol Pharmacol       Date:  1999-09       Impact factor: 4.436

Review 2.  Inverse agonism at heptahelical receptors: concept, experimental approach and therapeutic potential.

Authors:  L Daeffler; Y Landry
Journal:  Fundam Clin Pharmacol       Date:  2000 Mar-Apr       Impact factor: 2.748

3.  Disparate ligand-mediated Ca(2+) responses by wild-type, mutant Ser(200)Ala and Ser(204)Ala alpha(2A)-adrenoceptor: G(alpha15) fusion proteins: evidence for multiple ligand-activation binding sites.

Authors:  P J Pauwels; F C Colpaert
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

Review 4.  Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors.

Authors:  D Colquhoun
Journal:  Br J Pharmacol       Date:  1998-11       Impact factor: 8.739

5.  Facilitation of constitutive alpha(2A)-adrenoceptor activity by both single amino acid mutation (Thr(373)Lys) and g(alphao) protein coexpression: evidence for inverse agonism.

Authors:  P J Pauwels; S Tardif; T Wurch; F C Colpaert
Journal:  J Pharmacol Exp Ther       Date:  2000-02       Impact factor: 4.030

6.  Ligand-receptor interactions as controlled by wild-type and mutant Thr(370)Lys alpha2B-adrenoceptor-Galpha15 fusion proteins.

Authors:  P J Pauwels; S Tardif; F Finana; T Wurch; F C Colpaert
Journal:  J Neurochem       Date:  2000-01       Impact factor: 5.372

7.  Inverse agonism: pharmacological curiosity or potential therapeutic strategy?

Authors:  G Milligan; R A Bond; M Lee
Journal:  Trends Pharmacol Sci       Date:  1995-01       Impact factor: 14.819

8.  Modulation of 5-HT1A receptor signalling by point-mutation of cysteine351 in the rat Galpha(o) protein.

Authors:  D S Dupuis; S Tardif; T Wurch; F C Colpaert; P J Pauwels
Journal:  Neuropharmacology       Date:  1999-07       Impact factor: 5.250

9.  Alpha2-adrenoceptor agonists stimulate high-affinity GTPase activity in a receptor subtype-selective manner.

Authors:  C C Jansson; K Pohjanoksa; J Lang; S Wurster; J M Savola; M Scheinin
Journal:  Eur J Pharmacol       Date:  1999-06-11       Impact factor: 4.432

10.  G-protein activation by putative antagonists at mutant Thr373Lys alpha2A adrenergic receptors.

Authors:  T Wurch; F C Colpaert; P J Pauwels
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

View more
  2 in total

1.  Real-time analysis of dopamine: antagonist interactions at recombinant human D2long receptor upon modulation of its activation state.

Authors:  P J Pauwels; S Tardif; T Wurch; F C Colpaert
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

2.  Alpha 2A-adrenergic receptor signaling underlies synergistic enhancement of ethanol-induced behavioral impairment by clonidine.

Authors:  Tara Summer Bender; Abdel A Abdel-Rahman
Journal:  Alcohol Clin Exp Res       Date:  2008-12-13       Impact factor: 3.455

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.